News

Fibrocell Receives Rare Pediatric Disease Designation For FCX-007 To Treat Dystrophic Epidermolysis Bullosa (RDEB)

Fibrocell Science, Inc., an autologous gene and cell therapy firm developing first-in-class treatments to address scleroderma and connective tissue-related diseases, recently announced that the United States Food and Drug Administration (FDA) has awarded a rare pediatric disease designation for FCX-007. This is the Fibrocell’s main orphan gene-therapy drug candidate to treat recessive dystrophic epidermolysis bullosa…

SPARC Consortium Supports Research In Scleroderma

The Strategic Pharma-Academic Research Consortium for Translational Medicine has announced it is providing new grants that will support research into autoimmune diseases worth $1.9 million in total. The consortium is led by the Indiana Clinical and Translational Sciences Institute and is offering financial support for research projects involving scleroderma, dermatomyositis, lupus, multiple sclerosis and Crohn’s disease. Other…